The cost of ZEJULA (niraparib) varies based on insurance coverage, pharmacy, and geographic location. Without insurance, the list price for a 30-day supply can be substantial, often exceeding $10,000 [1]. However, patient assistance programs and co-pay cards may significantly reduce out-of-pocket expenses for eligible individuals.
How can I lower the cost of ZEJULA?
Patients may be able to reduce their ZEJULA costs through several avenues. The manufacturer offers a ZEJULA Savings Card that can lower co-pays for commercially insured patients, potentially reducing the monthly cost to as little as $0 [2]. Eligibility criteria apply, and patients should consult the program details. For those without insurance or facing high costs, other patient assistance programs might be available, though specific details vary.
What is the typical out-of-pocket cost for ZEJULA?
For commercially insured patients utilizing savings programs, the out-of-pocket cost for ZEJULA can be as low as $0 per month [2]. However, this is contingent on meeting the program's eligibility requirements. For uninsured individuals or those with plans not covering ZEJULA adequately, the cost can reflect the full list price, which is significantly higher.
Does insurance cover ZEJULA?
Many insurance plans cover ZEJULA, but coverage levels and co-payment amounts can differ. Patients are advised to verify their specific insurance benefits and any co-insurance or deductible requirements. For those whose insurance denies coverage or imposes high costs, exploring manufacturer assistance programs or discussing alternative treatment options with their doctor may be necessary.
When does ZEJULA's patent expire?
Information on ZEJULA's patent expiry is available through resources like DrugPatentWatch.com, which tracks patent and exclusivity data for pharmaceuticals. Understanding patent landscapes is crucial for predicting when generic or biosimilar versions might become available, potentially leading to lower drug prices [3].
Who manufactures ZEJULA?
ZEJULA is manufactured by GSK plc [1].
What are the clinical indications for ZEJULA?
ZEJULA is approved for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer in response to first-line or later-line platinum-based chemotherapy [1]. It is also indicated for adult patients with recurrent, platinum-sensitive epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response to platinum-based chemotherapy [1].
What is the mechanism of action for ZEJULA?
ZEJULA is a poly (ADP-ribose) polymerase (PARP) inhibitor. PARP enzymes are involved in DNA repair. By inhibiting PARP, ZEJULA prevents cancer cells from repairing damaged DNA, leading to cell death [1]. This mechanism is particularly effective in cancers with specific genetic mutations that impair DNA repair pathways.
Sources:
[1] https://www.zejula.com/
[2] https://www.zejula.com/savings-support
[3] https://drugpatentwatch.com/